

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

NCT07233239

Status	RECRUITING
Phase	Phase 1
Sponsor	Jazz Pharmaceuticals
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (12)

- Participants are eligible to be included in the main study only if all of the following criteria apply:
- Participant has a documented diagnosis of focal epilepsy according to the ILAE Classification of Epilepsy, 2017, characterized by focal seizure types with typical interictal/ictal EEG findings (eg, focal sharp waves or slowing).
- Participant is currently treated with at least 1, but no more than 4, antiseizure medications on a stable regimen.
- Participant is aged 12 to 75 years old, inclusive, at Screening.
- Participants are excluded from the study if any of the following criteria apply:
... and 7 more (see full listing online)

Locations (23 total)

Banner University Medical Center-Phoenix, Phoenix, Arizona, United States
UC San Diego, La Jolla, California, United States
Yale University, New Haven, Connecticut, United States
... and 20 more locations